JPRN-jRCT2080220058UnknownPhase 3
Phase 3 clinical study of AK-120 in patients with herpes zoster
ASAHIKASEI PHARMA CORPORATIO0 sitesStarted: September 8, 2005Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 3
- Sponsor
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- >= 20age old to <= 80age old (—)
- Sex
- All
Inclusion Criteria
- •Inclusion criteria
- •1) patients diagnosed with herpes zoster;
- •2) patients in whom the study drug can be administered within 72 hours of onset of the zoster rash;
- •3) patients in whom edematous erythema is observed before the development of vesicles are noted;
- •4) patients aged 20 to 80 years;
- •5) patient can be either male or female.
- •Exclusion criteria
- •1) patients with severe herpes zoster in whom sufficient therapeutic benefit cannot be anticipated from oral medication;
- •2) patients whose clinical conditions are diagnosed as evidencing either immunodeficiency or depressed immune functions;
- •3) patients with a past history of herpes zoster;
- •4) patients whose lesions have started to crust.
Exclusion Criteria
- Not provided
Investigators
Similar Trials
Completed
Phase 2
Phase 2 study of BKM120 in patients with advanced esophagus cancerJPRN-UMIN000011217ational Cancer Center Hospital East41
Unknown
Phase 2
Early Phase II clinical study of AK150 for the treatment of knee osteoarthritisKnee OsteoarthritisJPRN-jRCT2080221101ASAHI KASEI PHARMA CORPORATIO
Completed
Phase 3
Phase III Clinical Study on ART-123 in patients with disseminated intravascular coagulation (DIC) directly caused by malignant hematopoietic tumors or infections (Multicenter double-blind randomized parallel group comparative study with heparin sodium as control drug)Disseminated intravascular coagulation (DIC) directly caused by malignant hematopoietic tumors or infectionsJPRN-C000000327Asahi Kasei Pharma Corporation220
Unknown
Phase 3
Phase III Clinical Study on ART-123 in patients with disseminated intravascular coagulation (DIC) directly caused by malignant hematopoietic tumors or infectionsDisseminated intravascular coagulation (DIC)JPRN-jRCT2080220059ASAHIKASEI PHARMA CORPORATIO
Active, not recruiting
Phase 1
A phase II trial of BKM120 (a PI3K inhibitor) in patients with triple negative metastatic breast cancerEUCTR2011-006083-45-ESSOLTI (Grupo Español de Estudio, Tratamiento y Otras Estrategias Experimentales en Tumores Sólidos)50